Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;13(20):e70348.
doi: 10.1002/cam4.70348.

The Other Site of Rhabdomyosarcoma

Leonie Kern  1 , Anton Henssen  1 , Angelika Eggert  1 , Monika Scheer  1
Affiliations

The Other Site of Rhabdomyosarcoma

Leonie Kern et al. Cancer Med. 2024 Oct.

Abstract

Background: Rhabdomyosarcoma (RMS) is a rare malignant soft tissue sarcoma (STS), accounting for almost 50% of pediatric STSs. Due to its heterogeneity, RMS presents challenges in diagnosis and treatment, with prognosis varying depending on multiple factors. Tumors localized in the other site (OTH)-including the paraspinal, perianal, thoracic, abdominal, pelvic, and perineal regions-are generally classified as unfavorable. This study assesses the clinical features and prognoses of RMS in OTH locations depending on its site of origin.

Methods: An explorative analysis of RMS cases from the SEER 17 database 2000-2020 was conducted. Patients of all ages with histologically confirmed RMS as primary malignant disease classified under OTH, were included. OTH was categorized in four granular site classifications. Overall survival (OS) and disease-specific survival (DSS) were analyzed using Kaplan-Meier estimators. Factors independently influencing survival, including a site classification model presented in this study, were identified through Cox regression analysis.

Results: Out of 4168 patients with RMS, 990 cases of RMS with the OTH site met the inclusion criteria. The median age was 16 years. The predominant histological subtypes were embryonal (33.0%) and alveolar (25.5%). Most tumors were ≥ 5 cm (median 9 cm) and located primarily in the pelvic region (41.5%). The 3-, 5-, and 10-year OS rates were 45.4% ± 3.332 (95% CI), 40.7 ± 3.332, and 38.6% ± 3.332, respectively, while DSS rates were 43.3% ± 3.136 (95% CI), 38.3% ± 3.136, and 35.1% ± 3.332. In the multivariate analysis age, histological type, site in a granular categorization, stage, regional lymph node examination, and regional lymph node involvement (pathologically proven) were independently associated with survival. Through both univariate and multivariate analyses, an OTH favorable group could be established. The OTH favorable group consists of the anal region, gallbladder and biliary tract, and breast.

Conclusion: RMS in OTH shows significant differences in prognosis, putting the current categorization as unfavorable into question and making a more detailed classification necessary. Furthermore, pathological regional lymph node assessment is specifically in the OTH localization recommended.

Keywords: adult sarcoma; age; age‐spanning; lymph nodes; other site; pediatric sarcoma; rhabdomyosarcoma; soft tissue sarcoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
CONSORT diagram.
FIGURE 2
FIGURE 2
Survival.
FIGURE 3
FIGURE 3
DSS variables.
See this image and copyright information in PMC

References

    1. Ries L. A. G., Smith M. A., Gurney J. G., Linet M., Tamra T., and Young J. L., Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975‐1995, ed. Bunin G. R. (MD: Bethesda, 1999).
    1. Linet M. S., Ries L. A., Smith M. A., Tarone R. E., and Devesa S. S., “Cancer Surveillance Series: Recent Trends in Childhood Cancer Incidence and Mortality in the United States,” Journal of the National Cancer Institute 91, no. 12 (1999): 1051–1058. - PubMed
    1. Li J., Thompson T. D., Miller J. W., Pollack L. A., and Stewart S. L., “Cancer Incidence Among Children and Adolescents in the United States, 2001‐2003,” Pediatrics 121, no. 6 (2008): e1470–e1477. - PubMed
    1. Sultan I., Qaddoumi I., Yaser S., Rodriguez‐Galindo C., and Ferrari A., “Comparing Adult and Pediatric Rhabdomyosarcoma in the Surveillance, Epidemiology and End Results Program, 1973 to 2005: An Analysis of 2,600 Patients,” Journal of Clinical Oncology 27, no. 20 (2009): 3391–3397. - PubMed
    1. Dagher R. and Helman L., “Rhabdomyosarcoma: An Overview,” Oncologist 4, no. 1 (1999): 34–44. - PubMed

LinkOut - more resources